Atlas Trials

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT02013167 · TERMINATED

Trial details

NCT number
NCT02013167
Sponsor
Amgen
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Start date
2014-01-03
Primary completion
2015-12-29
Enrollment
405

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.